Clinical trials: Hepatic Tumors
NSCLC Stage IIIB, NSCLC Stage IV
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
This is a phase I clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce our patented…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IV, Hepatocellular Carcinoma by BCLC Stage, Lung Cancer
- Trial name
- NCT03515252
- Testing
- Immune Killer Cells (IKC)
- Volunteers
- 20 people
- Sponsor
- Ivy Life Sciences, Co., Ltd
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Hepatocellular Carcinoma
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)
The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma.
- Trial name
- NCT03463876
- Testing
- SHR 1210+apatinib
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Liver Cancer Registry Platform
The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics…
- Trial name
- JADE (NCT04510740)
- Testing
- Physician's choice according to patient's needs.
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- iOMEDICO AG
Hepatocellular Carcinoma
Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma
This is a single center and open-label study to determine the safety and efficacy of mRNA HBV-TCR redirected T-cells in HBV-related HCC who are not amenable to/failed conventional treatment.
- Trial name
- NCT06961617
- Testing
- LioCyx-M, HBV antigen-specific TCR-redirected T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Lion TCR Pte. Ltd.
HepatoCellular Carcinoma, Liver Cancer
Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy
The purpose of this study is to evaluate the efficacy of ex vivo expanded autologous immune killer cells in treating hepatocellular carcinoma patients in： 1. Reduction of tumor size 2.
- Trial name
- NCT03592706
- Testing
- IKC (Immune Killer Cells), TACE (Transcatheter Arterial Chemoembolization)
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Ivy Life Sciences, Co., Ltd
Carcinoma, Hepatocellular
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
To evaluate the safety, efficacy and PK of avelumab in combination with axitinib as first line treatment in patients with advanced HCC
- Trial name
- NCT03289533
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Researchers are looking for a better way to treat people diagnosed with liver cancer which may have spread to nearby tissue and is unlikely to be cured or controlled with treatment (advanced metastatic hepatocellular carcinoma…
- Trial name
- NCT04696055
- Testing
- Pembrolizumab, Regorafenib (Stivarga, BAY73-4506)
- Where
- 39 sites in United States, France and 6 more
- Volunteers
- 95 people
- Sponsor
- Bayer
Mild and Moderate Hepatic Impairment
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects with Normal and Impaired Hepatic Function
- Trial name
- NCT04116476
- Testing
- MT-7117
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma America, Inc.
Neoplasms
Asian Phase I Study Of PF-03446962
This is an Asian Phase 1, multi center, open label, single arm study of PF 03446962 with dose escalation and designed to define the Maximum Tolerated Dose [MTD] and the Recommended Phase 2 Dose [RP2D].
- Trial name
- NCT01337050
- Testing
- PF-03446962
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 36 people
- Sponsor
- Pfizer
Urothelial Carcinoma, Renal Cell Carcinoma
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types…
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer
- Trial name
- NCT03170960
- Testing
- cabozantinib, atezolizumab
- Where
- 124 sites in United States, Australia and 7 more
- Volunteers
- 914 people
- Sponsor
- Exelixis
Advanced Solid Tumor, Lung Cancer
A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.
This is a multicenter, open-label study conducted in 3 phases: Dose escalation stage: The stage contain 4 cohorts, each cohort divided into 2 groups （group A, single dose and Group B, multiple dose）.Dose escalation will use a 3+3…
- Conditions
- Advanced Solid Tumor, Lung Cancer, Liver Cancer, Lymphoma
- Trial name
- NCT05598268
- Testing
- T3011
- Where
- 7 sites in China
- Volunteers
- 74 people
- Sponsor
- ImmVira Pharma Co. Ltd
Carcinoma, Hepatocellular
A Phase II, Open-Label Trial Evaluating GV1001 in Advanced Hepatocellular Carcinoma.
The purpose of this study is to investigate the efficacy of GV1001 in locally advanced or metastatic HCC. Also the safety of GV1001 and immunogenicity will be evaluated.
- Trial name
- NCT00444782
- Testing
- GV1001
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 41 people
- Sponsor
- Pharmexa A/S
Advanced Hepatocellular Carcinoma
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common malignant disease worldwide with an increasing incidence in industrialized countries. For patients with advanced HCC no efficient treatment is currently available.
- Trial name
- NCT00241020
- Testing
- Octreotide
- Volunteers
- 270 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care…
- Conditions
- Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastases
- Trial name
- NCT03781934
- Testing
- MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, MIV-818 (fostroxacitabine bralpamide) + lenvatinib
- Where
- 18 sites in Belgium, South Korea and 2 more
- Volunteers
- 53 people
- Sponsor
- Medivir
Carcinoma, Hepatocellular
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in combination with sorafenib for subjects with unresectable HCC who have received no prior systemic therapy for HCC.
- Trial name
- NCT02323906
- Testing
- CC-122, Sorafenib
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Celgene
Uterine Cervical Neoplasms, Endometrial Neoplasms
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected…
- Conditions
- Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms
- Trial name
- NCT05007106
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib
- Where
- 73 sites in United States, Canada and 13 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study of INCA 0186 in Subjects With Advanced Solid Tumors
This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when…
- Conditions
- Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
- Trial name
- NCT04989387
- Testing
- INCA00186, Retifanlimab, INCB106385
- Where
- 32 sites in United States, Austria and 4 more
- Volunteers
- 57 people
- Sponsor
- Incyte Corporation
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer
- Trial name
- NCT05953337
- Testing
- EYE90 Microspheres Treatment
- Where
- 22 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- ABK Biomedical
Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
- Trial name
- NCT07493044
- Testing
- Super CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.